Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose aflibercept for suboptimally responsive polypoidal choroidal vasculopathy
ISRCTN40126490Phase 4Recruiting
- Sponsor
- Moorfields Eye Hospital
- Start
- Oct 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 4, open-label, single-arm trial of aflibercept in polypoidal choroidal vasculopathy (PCV) and exudative macular degeneration, sponsored by Moorfields Eye Hospital. Primary endpoint: Presence of polypoidal choroidal vasculopathy activity. Started Oct 2026; status: recruiting.
02
Drugs
aflibercept
03
Conditions
polypoidal choroidal vasculopathy (PCV)exudative macular degeneration
Beyond the preview
Go deeper on ISRCTN40126490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN40126490.